Cardiovascular changes after treatment with dexfenfluramine and yohimbine in obese women measured by thoracic electrical bioimpedance.
An anorectic drug, dexfenfluramine (dF) is commonly used in obesity treatment. The aim of our study was to investigate if dexfenfluramine used alone or together with alpha 2-adrenolitic yohimbine (Y), can change cardiovascular state in obese women.
Waluga
M
M
Department of Gastroenterology, Silesian Medical Academy, Katowice, Poland.
Janusz
M
M
Karpel
E
E
Hartleb
M
M
Nowak
A
A
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D001067:Appetite Depressants / Q000009:adverse effects* / Q000627:therapeutic use; D020372:Dexfenfluramine / Q000009:adverse effects* / Q000627:therapeutic use; D017097:Electric Impedance; D005080:Exercise Test; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D009765:Obesity / Q000188:drug therapy / Q000503:physiopathology*; D015016:Yohimbine / Q000009:adverse effects* / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D001067:Appetite Depressants; D015016:Yohimbine; D020372:Dexfenfluramine